It is made available under a CC-BY 4.0 International license.

Effects of Maternal Fortified Balanced Energy-Protein Supplementation on the Mother-Infant Gut Microbiome: A Sub-Study of the MISAME-III Randomized Controlled Trial

Lishi Deng^{1,*}[®], Steff Taelman^{2,3,4,*}[®], Matthew R. Olm⁵, Laéticia Céline Toé^{1,6}[®], Eva Balini⁴, Lionel Ouédraogo^{1,7} , Yuri Bastos-Moreira^{1,8} , Alemayehu Argaw¹ , Kokeb Tesfamariam¹ , Erica D. Sonnenburg⁵, Moctar Ouédraogo⁹[®], Rasmané Ganaba⁹[®], Wim van Criekinge²[®], Patrick Kolsteren¹^{(D}, Michiel Stock^{2,3}^{(D}, Carl Lachat¹^{(D}, Justin L. Sonnenburg^{5,10,11}, Trenton Dailey-Chwalibóg^{1,9}

- 1 Department of Food Technology, Safety and Health, Faculty of Bioscience Engineering, Ghent University, Ghent, Belgium.
2 BIOBIX Department of Data Analysis and Mathematical Modelling, Ghent University, 9000 Ghent, Belgiu
- 2 BIOBIX, Department of Data Analysis and Mathematical Modelling, Ghent University, 9000 Ghent, Belgium
- 3 KERMIT, Department of Data Analysis and Mathematical Modelling, Ghent University, 9000 Ghent, Belgium
- 4 BioLizard nv, Ghent, Belgium
- 5 Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA.
- 6 Institut de Recherche en Sciences de la Santé (IRSS), Unité Nutrition et Maladies Métaboliques.
- 7 Centre Muraz, Bobo-Dioulasso, Burkina Faso.
- 8 Center of Excellence in Mycotoxicology and Public Health, MYTOXSOUTH® Coordination Unit, Faculty of Pharmaceutical Sciences, Ghent University, 9000 Ghent, Belgium
- 9 Agence de Formation de Recherche et d'Expertise en Santé pour l'Afrique (AFRICSanté), Bobo-Dioulasso, Burkina Faso.
- 10 Chan Zuckerberg Biohub, San Francisco, CA, USA.
- 11 Center for Human Microbiome Studies, Stanford University School of Medicine, Stanford, CA, USA.
- * These authors contributed equally to the work
- Correspondence author: Trenton Dailey-Chwalibóg [Trenton@Dailey-Chwalibog.com]

Abstract

Biological pathways, including individual gut microbiome are potential barriers for maternal nutritional supplementation to improvement in infant growth. We evaluated the impact of balanced energy-protein (BEP) supplementation during pregnancy and the first six months of lactation on the composition and functionality of gut microbiome in mothers and their infants in rural Burkina Faso. Our findings reveal that BEP supplementation led to a significant increase in microbiome diversity during pregnancy. In the second trimester, there was a notable decrease in the abundance of an *Oscillospiraceae* species, while postpartum, the abundance of *Bacteroides fragilis* increased. We identified concerted enriched or depleted microbial pathways associated with BEP supplementation, including the phosphotransferase system, a critical mechanism for bacterial carbohydrates uptake, which exhibited enrichment in infants born to BEP-supplemented mothers. Despite these observations, the intricate biological connections with other omics necessitate further analysis to fully elucidate the underlying comprehensive biological pathways.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

¹**Introduction**

2 It estimated that 148.1 million children under the age of 5 – about 22% of the global
3 population - experienced stunted growth in 2022, hindering their full developmental 3 population - experienced stunted growth in 2022, hindering their full developmental
4 potential¹. Stunted growth commonly begins before birth. so-called fetal growth restriction q 4 potential¹. Stunted growth commonly begins before birth, so-called fetal growth restriction
5 and accumulates during infancy until the age of 18 to 23 months; after 2 years of age, the 5 and accumulates during infancy until the age of 18 to 23 months; after 2 years of age, the growth impairment tends to be largely irreversible²⁻⁵. Maternal undernutrition in pregnancy is growth impairment tends to be largely irreversible^{2–5}. Maternal undernutrition in pregnancy is

7 a maior risk factor for poor child growth^{2,5}. A growing body of research has investigated the a major risk factor for poor child growth^{2,5}. A growing body of research has investigated the effect of maternal nutritional supplementation on infant growth, such as lipid-based nutrient 8 effect of maternal nutritional supplementation on infant growth, such as lipid-based nutrient
9 supplement (LNS) and balanced energy-protein (BEP), but the results have been mixed $6-10$. supplement (LNS) and balanced energy-protein (BEP), but the results have been mixed^{6–10}.
10 These findings suggest that the role of biological pathways needs to be considered. These findings suggest that the role of biological pathways needs to be considered.

11 From the first colonization of the neonate at birth through maternal microbiota, succession in
12 bacterial taxa differ based on geographical area^{11–13}, feeding practice^{14,15}, dietary patterns, age, bacterial taxa differ based on geographical area^{11–13}, feeding practice^{14,15}, dietary patterns, age,

and health status^{16,17}. A more mature gut microbiota at the first month may improve infant and health status^{16,17}. A more mature gut microbiota at the first month may improve infant
14. growth trajectories in the first vear of life¹⁸. Inadequate maturation of the gut microbiome growth trajectories in the first year of life¹⁸. Inadequate maturation of the gut microbiome
15. might contribute to the onset of child malnutrition, and both microbiome immaturity and 15 might contribute to the onset of child malnutrition, and both microbiome immaturity and
16 malnutrition can be partially ameliorated following nutrition interventions^{19,20} Therefore. malnutrition can be partially ameliorated following nutrition interventions^{19,20}. Therefore,
17 eiven its plastic nature, the individual gut microbiome appears to be a promising barrier to 17 given its plastic nature, the individual gut microbiome appears to be a promising barrier to
18 improvement in growth outcomes. improvement in growth outcomes.

19 The evidence on the effect of maternal nutritional supplementation on infant gut microbiome
20 is scarce. Two analyses based on randomized controlled trials (RCTs) in Malawi showed 20 is scarce. Two analyses based on randomized controlled trials (RCTs) in Malawi showed
21 inconsistent results. The first study ($n = 869$) revealed a significant enhancement in alpha 21 inconsistent results. The first study ($n = 869$) revealed a significant enhancement in alpha
22 diversity among infants receiving LNS from 6 to 18 months²¹, while the second study ($n =$ diversity among infants receiving LNS from 6 to 18 months²¹, while the second study ($n =$ 631) demonstrated no statistically significant effects of LNS on the diversity and maturation 23631) demonstrated no statistically significant effects of LNS on the diversity and maturation
24 of the infant gut microbiota in samples collected between 6 and 30 months of age²². of the infant gut microbiota in samples collected between 6 and 30 months of age²².

25 BEP supplements are a similar type of ready-to-use supplements that provide multiple micronutrients and, specifically, energy and protein in a balanced composition \langle <25% of total 26 micronutrients and, specifically, energy and protein in a balanced composition \langle 25% of total
27 energy content from protein) to address maternal malnutrition during pregnancy and lactation. 27 energy content from protein) to address maternal malnutrition during pregnancy and lactation.
28 We previously reported that, in the MIcronutriments pour la SAnté de la Mere et de l'Enfant-28 We previously reported that, in the MIcronutriments pour la SAnté de la Mere et de l'Enfant-
29 III (MISAME-III) trial. BEP supplementation increase energy and macro- and micronutrient 29 III (MISAME-III) trial, BEP supplementation increase energy and macro- and micronutrient
30 intakes among pregnant women and fills nutrient gaps without displacing food intake²³. intakes among pregnant women and fills nutrient gaps without displacing food intake²³.
31. Moreover, we observed a modest effect of prenatal BEP supplementation on weight and 31 Moreover, we observed a modest effect of prenatal BEP supplementation on weight and
32 length increments at birth, and on the prevalence of low birth weight²⁴. The improvements in length increments at birth, and on the prevalence of low birth weight²⁴. The improvements in

It is made available under a CC-BY 4.0 International license.

33 size at birth accrued from prenatal BEP supplementation were sustained in terms of linear
34 growth at the age of 6 months⁷. However, the impact of providing pregnant and lactating growth at the age of 6 months⁷. However, the impact of providing pregnant and lactating
35. women with BEP supplementation on gut microbiota has vet to be investigated. women with BEP supplementation on gut microbiota has yet to be investigated.

36 The objective of the present study was to evaluate the efficacy of BEP supplementation
37 during pregnancy and the first six months of lactation in influencing the gut microbiota in 37 during pregnancy and the first six months of lactation in influencing the gut microbiota in
38 both mothers and infants, compared to the control group who received iron folic acid (IFA) 38 both mothers and infants, compared to the control group who received iron folic acid (IFA)
39 tablets. This encompasses an examination of the maternal and infant metagenome in terms of 39 tablets. This encompasses an examination of the maternal and infant metagenome in terms of
40 microbial composition and functionality, including microbial metabolic pathways, a 40 microbial composition and functionality, including microbial metabolic pathways, a
41 dimension that has not been explored in prior studies. dimension that has not been explored in prior studies.

⁴²**Results**

⁴³**Study population**

44 A total of 731 fecal samples from 152 pregnant and lactating women and their infants ($n = 71$
45 in BEP group and $n = 81$ in IFA group) were collected and sequenced; these comprised 256 45 in BEP group and $n = 81$ in IFA group) were collected and sequenced; these comprised 256 infant samples and 475 maternal samples. In the IFA group, infant samples were taken at two 46 infant samples and 475 maternal samples. In the IFA group, infant samples were taken at two
47 time points. 1-2 months (76 samples) and 5-6 months (56 samples) of life, and maternal 47 time points, 1-2 months (76 samples) and 5-6 months (56 samples) of life, and maternal
48 samples were taken at four time points, inclusion (i.e., trimester 2, 20 samples), trimester 3 48 samples were taken at four time points, inclusion (i.e., trimester 2, 20 samples), trimester 3
49 (78 samples), 1-2 months (76 samples) and 5-6 months (75 samples) postpartum (total IFA 49 (78 samples), 1-2 months (76 samples) and 5-6 months (75 samples) postpartum (total IFA
50 samples = 381). In the BEP group, 66 and 58 infant samples were taken at 1-2 months and 5-50 samples = 381). In the BEP group, 66 and 58 infant samples were taken at 1-2 months and 5-
51 6 months of life, and 22, 71, 66 and 67 maternal samples were taken at inclusion, trimester 3, 51 6 months of life, and 22, 71, 66 and 67 maternal samples were taken at inclusion, trimester 3,
52 1-2 months and 5-6 months postpartum (total BEP samples = 350) (Figure 1). 1-2 months and 5-6 months postpartum (total BEP samples $=$ 350) (Figure 1).

53 Baseline characteristics of study participants are presented in Table 1. The Mean age of the
54 study women was 24.27 (SD: 5.55) years, and the average body-mass index (BMI) was 22.37 54 study women was 24.27 (SD: 5.55) years, and the average body-mass index (BMI) was 22.37
55 kg/m². The Mean gestational age at birth was 39.82 (SD: 1.72) weeks and more than one in $kg/m²$. The Mean gestational age at birth was 39.82 (SD: 1.72) weeks and more than one in
56 three had at least three prior pregnancies. More than half of the women were from food-56 three had at least three prior pregnancies. More than half of the women were from food-
57 insecure households, and 30.3% were anemic. Almost all infants were exclusively breastfed. 57 insecure households, and 30.3% were anemic. Almost all infants were exclusively breastfed,
58 with an average duration of 5.78 months. Among all participants, the average compliance rate 58 with an average duration of 5.78 months. Among all participants, the average compliance rate
59 of consuming the BEP supplement was 83.1% during the prenatal and 86.0% during the 59 of consuming the BEP supplement was 83.1% during the prenatal and 86.0% during the postnatal supplementation periods. postnatal supplementation periods.

61 Deep sequencing of gut microbiome and the early colonization
62 Mean total sequencing depth of infant and maternal metagenome

62 Mean total sequencing depth of infant and maternal metagenomes was 8.03 (SD: 1.87) and
63 25.29 (SD: 5.28) giga base-pairs, respectively (Figure S1), 7.4% (SD: 1.7%) and 19.9% (SD:

⁶³25.29 (SD: 5.28) giga base-pairs, respectively (Figure S1). 7.4% (SD: 1.7%) and 19.9% (SD:

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

64 18.8%) of metagenomic reads were removed from maternal and infant samples during QC
65 and human read decontamination. 58.1% (SD: 14.2%) of infant and 58.0% (SD: 3.0%) 65 and human read decontamination. 58.1% (SD: 14.2%) of infant and 58.0% (SD: 3.0%)
66 maternal reads could be robustly assigned to genomes in our microbial genome database. Out 66 maternal reads could be robustly assigned to genomes in our microbial genome database. Out
67 of the 2.654 unique genomes detected in at least one sample, 2.493 are unique to the maternal 67 of the 2,654 unique genomes detected in at least one sample, 2,493 are unique to the maternal
68 population, 396 are unique to the infant population, and 235 are observed in both groups. 68 population, 396 are unique to the infant population, and 235 are observed in both groups.
69 Among the shared microbial genomes. 205 are already observed in the mothers at prenatal 69 Among the shared microbial genomes, 205 are already observed in the mothers at prenatal
60 The material gut microbiomes were dominated by *Prevotella* species. 70 time points. The maternal gut microbiomes were dominated by *Prevotella* species,
71 representing a median of 37.9% of the composition, with no maior shift between pre- and 71 representing a median of 37.9% of the composition, with no major shift between pre- and
72 postnatal compositions (38.1% and 37.7%). In the infant gut microbiomes. *Prevotella* 72 postnatal compositions (38.1% and 37.7%). In the infant gut microbiomes, *Prevotella*
73 comprised between 0.0% and 83.9% of the gut microbiome, despite being only observed in 73 comprised between 0.0% and 83.9% of the gut microbiome, despite being only observed in
74 44 out of the 256 infant samples. In most infant samples. *Bifidobacterium* strains were 74 44 out of the 256 infant samples. In most infant samples, *Bifidobacterium* strains were
75 dominant comprising a median of 44.5% of the microbial compositions and present in 98.0% 75 dominant, comprising a median of 44.5% of the microbial compositions and present in 98.0%
76 of infant samples (Figure 2A). of infant samples (Figure 2A).

⁷⁷**BEP supplementation has minimal effect on prenatal gut microbiome composition and** ⁷⁸**diversity**

79 The richness of the infant microbiota is markedly smaller than those of the mothers, with an
80 observed species index between 2 and 43 in the former and between 75 and 614 in the latter. 80 observed species index between 2 and 43 in the former and between 75 and 614 in the latter.
81 The Shannon diversity index has a median of 1.48 bits in the infant samples and 4.47 bits in 81 The Shannon diversity index has a median of 1.48 bits in the infant samples and 4.47 bits in
82 the maternal samples and is on average higher in the prenatal samples than in the postnatal 82 the maternal samples and is on average higher in the prenatal samples than in the postnatal
83 ones (Figure 2E). Using Targeted Maximum Likelihood Estimator (TMLE), a significant ($p =$ 83 ones (Figure 2E). Using Targeted Maximum Likelihood Estimator (TMLE), a significant ($p=$ 84 0.037) effect of BEP is observed on the prenatal maternal microbiome diversity. The average 84 0.037) effect of BEP is observed on the prenatal maternal microbiome diversity. The average
85 treatment effect is estimated at an increase in Shannon diversity index of 0.144 bits caused by 85 treatment effect is estimated at an increase in Shannon diversity index of 0.144 bits caused by
86 BEP supplementation (95% CI: 0.009 - 0.280). In effective numbers, this translates to an 86 BEP supplementation (95% CI: 0.009 - 0.280). In effective numbers, this translates to an
87 estimated increase of 1.16 equally common species due to the treatment. No significant 87 estimated increase of 1.16 equally common species due to the treatment. No significant average treatment effect was found on the postnatal ($p = 0.97$) and infant ($p = 0.11$) gut 88 average treatment effect was found on the postnatal $(p = 0.97)$ and infant $(p = 0.11)$ gut microbiome diversities. microbiome diversities.

90 As illustrated in Figure 2B and 2C, beta-diversity analyses show diversification of the
91 communities, with significant differences between samples taken at different stages of 91 communities, with significant differences between samples taken at different stages of
92 organization of $p = 0.002$ or infancy ($p = 0.001$). In the maternal samples, a marginally 92 pregnancy ($p = 0.002$) or infancy ($p = 0.001$). In the maternal samples, a marginally
93 significant ($p = 0.098$) inter-community difference is attributed to the BEP supplementation. 93 significant ($p = 0.098$) inter-community difference is attributed to the BEP supplementation,
94 though this effect is no longer observed in the infant samples ($p = 0.960$). though this effect is no longer observed in the infant samples ($p = 0.960$).

It is made available under a CC-BY 4.0 International license.

95 Differential abundance analyses in the maternal stool samples show significant associations
96 between an *Oscillospiraceae* species [CAG-103 sp 000432375; *q*-value = 2.48×10^{-4} ; log fold between an *Oscillospiraceae* species [CAG-103 sp 000432375; *q*-value = 2.48×10⁻⁴; log fold
97 change (logFC) = -1.121 and *Bacteroides fragilis* (*a*-value = 3.26×10⁻⁸; logFC = 1.31) and change (logFC) = -1.12] and *Bacteroides fragilis* (*q*-value = 3.26×10^{-8} ; logFC = 1.31) and
98 BEP supplementation, at inclusion and 5-6 months postpartum, respectively. No robustly 98 BEP supplementation, at inclusion and 5-6 months postpartum, respectively. No robustly
99 significant associations were found between BEP supplementation and the microbial 99 significant associations were found between BEP supplementation and the microbial abundances in the infant stool at either time point (Figure 3 and Table S2). abundances in the infant stool at either time point (Figure 3 and Table S2).

101 **BEP supplementation shows coordinated enrichment of specific microbial pathways**
102 Though no significant association was observed between the treatment intervention and

102 Though no significant association was observed between the treatment intervention and the
103 abundance of individual microbial genes, the Gene Set Enrichment Analysis did indicate 103 abundance of individual microbial genes, the Gene Set Enrichment Analysis did indicate
104 concerted enrichment and depletion of certain microbial pathways at each time point (Figure 104 concerted enrichment and depletion of certain microbial pathways at each time point (Figure
105 4). The gene set for the phosphotransferase system is found to be slightly depleted in the stool 105 4). The gene set for the phosphotransferase system is found to be slightly depleted in the stool
106 of BEP-supplemented mothers, both pre- and postpartum $(p=2.56\times10^{-5}$ at tri3; $p=2.23\times10^{-3}$ at of BEP-supplemented mothers, both pre- and postpartum $(p=2.56\times10^{-5}$ at tri3; $p=2.23\times10^{-3}$ at pn56) and enriched in stool of BEP-supplemented infants $(p=2.67\times10^{-2}$ at pn12; $p=2.76\times10^{-3}$ pn56) and enriched in stool of BEP-supplemented infants $(p=2.67\times10^{-2}$ at pn12; $p=2.76\times10^{-3}$ at pn56). Pathways for lipopolysaccharide (LPS) biosynthesis $(p=1.53\times10^{-4}$ at tri3;
109 $p=1.88\times10^{-2}$ at pn56). ABC transporters $(p=2.27\times10^{-8}$ at tri3; $p=1.17\times10^{-3}$ at pn56). 109 $p=1.88\times10^{-2}$ at pn56), ABC transporters $(p=2.27\times10^{-8}$ at tri3; $p=1.17\times10^{-3}$ at pn56), 110 biosynthesis of cofactors $(p=2.27\times10^{-8}$ at tri3: $p=1.42\times10^{-2}$ at pn56), and porphyrin biosynthesis of cofactors $(p=2.27\times10^{-8}$ at tri3; $p=1.42\times10^{-2}$ at pn56), and porphyrin
111 metabolism $(p=2.85\times10^{-3}$ at tri3; $p=1.74\times10^{-2}$ at pn56) are slightly, but significantly depleted metabolism ($p=2.85\times10^{-3}$ at tri3; $p=1.74\times10^{-2}$ at pn56) are slightly, but significantly depleted
112 in the BEP supplemented mothers at multiple time points. The pathway for the ribosome 112 in the BEP supplemented mothers at multiple time points. The pathway for the ribosome
113 complex is significantly enriched in the BEP-supplemented mothers at multiple time points 113 complex is significantly enriched in the BEP-supplemented mothers at multiple time points
114 $(p=1.55\times10^{-6}$ at tri3: $p=1.17\times10^{-3}$ at pn56). Other pathways, like those for flagellar assembly. $(p=1.55\times10^{-6}$ at tri3; $p=1.17\times10^{-3}$ at pn56). Other pathways, like those for flagellar assembly, 115 are enriched at inclusion (9.35 \times 10⁻⁵) yet depleted in the third trimester ($p=1.45\times10^{-5}$) and 1-2 months postpartum $(p=2.95\times10^{-8})$ in the BEP supplemented mothers. The full table of significantly differential pathways is available in Table S3. significantly differential pathways is available in Table S3.

118 In Figure 5, we show that the gene set depletion of the LPS biosynthesis pathway affects
119 specific sections of sequential genes in the pathway. Every gene involved in the conversion 119 specific sections of sequential genes in the pathway. Every gene involved in the conversion
120 from UDP-N-acetyl-D-glucosamine to Laurovl-KDO2-lipid IV(A) is less abundant with 120 from UDP-N-acetyl-D-glucosamine to Lauroyl-KDO2-lipid IV(A) is less abundant with
121 logFC from -0.033 (LpxH) to -0.140 (LpxC). Only one enriched gene, HddA, appears in the 121 logFC from -0.033 (LpxH) to -0.140 (LpxC). Only one enriched gene, HddA, appears in the
122 LPS biosynthesis pathway in another section of differentially abundant genes following the 122 LPS biosynthesis pathway in another section of differentially abundant genes following the
123 pentose phosphate pathway. Analogous pathway visualizations are available for the 123 pentose phosphate pathway. Analogous pathway visualizations are available for the phosphotransferase system, flagellar assembly, and ABC transporters in Supplementary Data 124 phosphotransferase system, flagellar assembly, and ABC transporters in Supplementary Data
125 (Figure S2-S4). $(Figure S2-S4)$.

It is made available under a CC-BY 4.0 International license.

¹²⁶**Discussion**

127 Here, we represent a rare combination of deep sequencing depth and high sample size on a
128 population that is underrepresented in metagenomic literature²⁵. We present three novel population that is underrepresented in metagenomic literature²⁵. We present three novel
129. findings. First, there is a striking disparity in composition of gut microbiome between 129 findings. First, there is a striking disparity in composition of gut microbiome between
130 mothers and their infants in rural Burkina Faso – the infant gut microbiota exhibited a 130 mothers and their infants in rural Burkina Faso – the infant gut microbiota exhibited a
131 conspicuous dominance of *Bifidobacterium* strains, while *Prevotella* species were dominant 131 conspicuous dominance of *Bifidobacterium* strains, while *Prevotella* species were dominant
132 in maternal samples. Second. BEP supplementation has minimal effect on maternal gut 132 in maternal samples. Second, BEP supplementation has minimal effect on maternal gut
133 microbiome – increased Shannon diversity and decreased the abundance of an 133 microbiome – increased Shannon diversity and decreased the abundance of an
134 *Oscillospiraceae* species during pregnancy and increased the abundance of *Bacteroides* ¹³⁴*Oscillospiraceae* species during pregnancy and increased the abundance of *Bacteroides* 135 *fragilis* postpartum. Finally, we observed multiple concerted enriched or depleted microbial
136 pathways associated with BEP supplementation, of which, the pathway phosphotransferase 136 pathways associated with BEP supplementation, of which, the pathway phosphotransferase
137 system, a maior mechanism used by bacteria for uptake of carbohydrates²⁶, is enriched in system, a major mechanism used by bacteria for uptake of carbohydrates²⁶, is enriched in infant samples whose mother were BEP-supplemented. infant samples whose mother were BEP-supplemented.

139 *Bifidobacterium*, commonly found in exclusively breastfed infants, are crucial in the infant
140 eut because they breakdown human milk oligosaccharides (HMO) to short chain fatty acids 140 gut because they breakdown human milk oligosaccharides (HMO) to short chain fatty acids
141 to maintain gut health^{27,28}. In this study, nearly all infants, regardless of intervention groups, to maintain gut health^{27,28}. In this study, nearly all infants, regardless of intervention groups,
142. experienced exclusive breastfeeding during the sample collection period. This circumstance 142 experienced exclusive breastfeeding during the sample collection period. This circumstance
143 might explain the comparability in abundance patterns between the groups and suggests that 143 might explain the comparability in abundance patterns between the groups and suggests that
144 the provision of BEP during pregnancy and lactation exerted no discernible impact on the 144 the provision of BEP during pregnancy and lactation exerted no discernible impact on the
145 primary beneficial colonizers or of their HMO utilization genes in infants. Previous 145 primary beneficial colonizers or of their HMO utilization genes in infants. Previous
146 researches highlighting the prevalence of *Prevotella*-rich gut in non-industrialized 146 researches highlighting the prevalence of *Prevotella*-rich gut in non-industrialized
147 populations, particularly those adhering to high-fiber diets, in stark contrast to the lower 147 populations, particularly those adhering to high-fiber diets, in stark contrast to the lower
148 occurrence observed in industrialized and westernized nations^{11,17,29}. This distinct enterotype occurrence observed in industrialized and westernized nations^{11,17,29}. This distinct enterotype
149. Characterized by *Prevotella* enrichment had also been noted in early childhood, spanning a 149 characterized by *Prevotella* enrichment had also been noted in early childhood, spanning a
150 wide age from 7 to 37 months, as observed in a Gambian cohort²⁹. Interestingly, we observed wide age from 7 to 37 months, as observed in a Gambian cohort²⁹. Interestingly, we observed
151. a strong tie of *Prevotella* between microbial genomes in mother and infant samples. In the 151 a strong tie of *Prevotella* between microbial genomes in mother and infant samples. In the
152 latter. *Prevotella* was either markedly absent or notably abundant, implying its swift 152 latter, *Prevotella* was either markedly absent or notably abundant, implying its swift
153 dominance within the ecological niche upon establishing residence within the infantile gut. ¹⁵³dominance within the ecological niche upon establishing residence within the infantile gut.

154 Gut microbiome alpha diversity has been linked to human health, with lower levels of diversity associated with several acute and chronic disease³⁰. Recent studies have reported a diversity associated with several acute and chronic disease³⁰. Recent studies have reported a
156. noteworthy association between a high-fat diet and a decrease alpha diversity, concomitant 156 noteworthy association between a high-fat diet and a decrease alpha diversity, concomitant
157 with the onset of low-grade inflammation^{31,32}. This in turn facilitate the increase and with the onset of low-grade inflammation^{31,32}. This in turn facilitate the increase and

It is made available under a CC-BY 4.0 International license.

translocation of bacterial products such as pro-inflammatory LPS^{33} . Intriguingly, our findings indicate the contrary: an augmentation in alpha diversity and a concurrent decrease in LPS 159 indicate the contrary: an augmentation in alpha diversity and a concurrent decrease in LPS
160 synthesis within the prenatal gut microbiota in women who received BEP. The subsection of 160 synthesis within the prenatal gut microbiota in women who received BEP. The subsection of
161 the LPS biosynthesis pathway which is depleted, *i.e.*, the central KDO and Lipid A 161 the LPS biosynthesis pathway which is depleted, *i.e.*, the central KDO and Lipid A
162 metabolism, is highly conserved and invariant in the gut microbiome of healthy individuals³⁴. metabolism, is highly conserved and invariant in the gut microbiome of healthy individuals³⁴.
163. Given that different covalent modifications of Lipid A also have different immunological 163 Given that different covalent modifications of Lipid A also have different immunological
164 properties^{35,36}, follow-up research integrating proteomics and metabolomics data is currently 164 properties^{35,36}, follow-up research integrating proteomics and metabolomics data is currently
165 ongoing to fully understand the clinical implications of these findings. ongoing to fully understand the clinical implications of these findings.

166 The observed significant variation in alpha diversity within the maternal gut microbiota
167 during pregnancy, without a corresponding effect among infants, suggests that the maternal 167 during pregnancy, without a corresponding effect among infants, suggests that the maternal
168 component of BEP supplementation did not exert a detectable influence on the diversity of 168 component of BEP supplementation did not exert a detectable influence on the diversity of
169 child's microbiome. This aligns with the observations stemming from an LNS intervention 169 child's microbiome. This aligns with the observations stemming from an LNS intervention
170 conducted in rural Malawi²¹. conducted in rural Malawi²¹.

171 We observed a significant association between BEP supplementation during the second
172 trimester and a reduction in the abundance of CAG-103 sp000432375, an *Oscillospiraceae* 172 trimester and a reduction in the abundance of CAG-103 sp000432375, an *Oscillospiraceae*
173 species that has recently been recognized as responsive to carbohydrates³⁷. The overall lesser species that has recently been recognized as responsive to carbohydrates³⁷. The overall lesser
174. dependence on carbohydrate metabolism can also be observed in the concerted depletion of 174 dependence on carbohydrate metabolism can also be observed in the concerted depletion of
175 genes for the phosphotransferase system and ABC transporters in the maternal 175 genes for the phosphotransferase system and ABC transporters in the maternal
176 metagenomes^{38,39}. In addition, BEP supplementation is associated with increased abundance netagenomes^{38,39}. In addition, BEP supplementation is associated with increased abundance
177 of *Bacteroides fragilis* within the maternal gut at 5-6 months postpartum. *B. fragilis* is a 177 of *Bacteroides fragilis* within the maternal gut at 5-6 months postpartum. *B. fragilis* is a
178 major component of the fecal microbiome, with potentially billions of *B* fragilis within the 178 major component of the fecal microbiome, with potentially billions of *B. fragilis* within the
179 gastrointestinal tract⁴⁰, and plays a crucial role in the degradation of host-derived mucosal gastrointestinal tract⁴⁰, and plays a crucial role in the degradation of host-derived mucosal
180 glycans, including mucins and the N-link oligosaccharides of glycoproteins⁴¹. Nevertheless, glycans, including mucins and the *N*-link oligosaccharides of glycoproteins⁴¹. Nevertheless,
181. during the third trimester, a contrasting association was observed between BEP 181 during the third trimester, a contrasting association was observed between BEP
182 supplementation and another strain of *B. fragilis*. However, it is important to exercise caution 182 supplementation and another strain of *B. fragilis*. However, it is important to exercise caution
183 when interpreting this finding, as it did not withstand the sensitivity analysis for pseudo-183 when interpreting this finding, as it did not withstand the sensitivity analysis for pseudo-
184 counts, suggesting the possibility of a false positive result. counts, suggesting the possibility of a false positive result.

185 Despite the potential for false positives, BEP supplementation appears to exhibit an association with the increases in the abundance of *Campylobacter jejuni*, and *Veillonella* 186 association with the increases in the abundance of *Campylobacter jejuni*, and *Veillonella*
187 *parvula* and *Klebsiella auasipneumoniae* during the first two months and at the five-to-six 187 parvula and *Klebsiella quasipneumoniae* during the first two months and at the five-to-six
188 months of early life, respectively. In LMICs, infection with *Campylobacter* is one of the 188 months of early life, respectively. In LMICs, infection with *Campylobacter* is one of the
189 maior causes of diarrheal disease in children⁴², leading to early protein malnutrition⁴³. A major causes of diarrheal disease in children⁴², leading to early protein malnutrition⁴³. A

It is made available under a CC-BY 4.0 International license.

190 recent study has reported higher rates of campylobacteriosis among exclusively breastfed
191 infants in LMICs. It suggests that specific *C. jejuni* strains can utilize HMO and proteins in 191 infants in LMICs. It suggests that specific *C. jejuni* strains can utilize HMO and proteins in
192 human milk to promote the growth of campylobacters⁴⁴. Similarly, another study revealed human milk to promote the growth of campylobacters⁴⁴. Similarly, another study revealed
193. that the content of the secretory immunoglobulin A $(SIgA)$ in breastmilk was positively 193 that the content of the secretory immunoglobulin A (sIgA) in breastmilk was positively
194 correlated with the abundance of *V. parvula* in infant gut microbiota, and suggested that this 194 correlated with the abundance of *V. parvula* in infant gut microbiota, and suggested that this
195 regulation during early life is one of the potential mechanisms by which sIgA in breast milk 195 regulation during early life is one of the potential mechanisms by which sIgA in breast milk
196 modulates immune function⁴⁵. *Klebsiella pneumoniae*, comprising *K. auasipneumoniae*, is a modulates immune function⁴⁵. *Klebsiella pneumoniae*, comprising *K. quasipneumoniae*, is a
197 leading pathogen for neonatal infection^{46,47}. A recent study has reported the association of the leading pathogen for neonatal infection^{46,47}. A recent study has reported the association of the
198. high abundance of *Klebsiella* and high content of breast milk N-acetylneuraminic acid 198 high abundance of *Klebsiella* and high content of breast milk N-acetylneuraminic acid
199 (Neu5Ac), the predominant form of free salic acid and important component binding to 199 (Neu5Ac), the predominant form of free salic acid and important component binding to
200 sialvlated oligosaccharides in breast milk, which indicates that *Klebsiella* could utilize sialic 200 sialylated oligosaccharides in breast milk, which indicates that *Klebsiella* could utilize sialic
201 acid as carbon source⁴⁸. Hence, the observed connection between BEP supplementation and acid as carbon source⁴⁸. Hence, the observed connection between BEP supplementation and
202. increased abundance of these species in the infant gut microbiome imply that BEP 202 increased abundance of these species in the infant gut microbiome imply that BEP
203 supplementation during pregnancy and lactation may influence the infant microbiome by 203 supplementation during pregnancy and lactation may influence the infant microbiome by
204 impacting the composition of human milk. However, further analyses aimed at evaluating the 204 impacting the composition of human milk. However, further analyses aimed at evaluating the
205 effect of BEP supplementation on breastmilk composition are imperative to gain a more 205 effect of BEP supplementation on breastmilk composition are imperative to gain a more
206 comprehensive understanding of these observations. comprehensive understanding of these observations.

207 We identified that the phosphotransferase system, a critical mechanism for bacterial
208 carbohydrates untake, exhibited enrichment in infants born to BEP-supplemented mothers. 208 carbohydrates uptake, exhibited enrichment in infants born to BEP-supplemented mothers.
209 This implies that the provision of BEP supplementation to mothers may elevate carbohydrate 209 This implies that the provision of BEP supplementation to mothers may elevate carbohydrate
210 content in human milk, thereby augmenting the bacterial carbohydrates uptake capacity 210 content in human milk, thereby augmenting the bacterial carbohydrates uptake capacity
211 within the infant gut, potentially contributing to enhanced linear growth. However, 211 within the infant gut, potentially contributing to enhanced linear growth. However,
212 subsequent analyses, incorporating a detailed evaluation of human milk components and 212 subsequent analyses, incorporating a detailed evaluation of human milk components and
213 emploving a multi-omics approach are imperative for a comprehensive understanding of the 213 employing a multi-omics approach are imperative for a comprehensive understanding of the
214 intricate biological pathways. intricate biological pathways.

215 Some significantly differential pathways were found that are unlikely to be of microbial
216 origin, such as those for the ribosome complex, the biosynthesis of cofactors, and porphyrin 216 origin, such as those for the ribosome complex, the biosynthesis of cofactors, and porphyrin
217 metabolism. Though the observation of these pathways is likely a limitation of the KEGG 217 metabolism. Though the observation of these pathways is likely a limitation of the KEGG
218 database these genes were annotated with, their consistent association to the BEP 218 database these genes were annotated with, their consistent association to the BEP
219 supplemented metagenome can be indication that there are so far unknown microbial 219 supplemented metagenome can be indication that there are so far unknown microbial processes that involve these genes. 220 processes that involve these genes.
221

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

²²²**Methods**

223 **Study setting and design**
224 The MISAME-III study pr

The MISAME-III study protocol⁴⁹ and the biospecimen sub-study (Biospé)⁵⁰ were published
225 earlier. Briefly, the MISAME-III trial (NCT03533712) is an individually randomized 2 x 2 225 earlier. Briefly, the MISAME-III trial (NCT03533712) is an individually randomized 2 x 2
226 factorial RCT evaluating the efficacy of multiple micronutrient-fortified BEP 226 factorial RCT evaluating the efficacy of multiple micronutrient-fortified BEP
227 supplementation during pregnancy and lactation on birth outcomes and infant growth in rural 227 supplementation during pregnancy and lactation on birth outcomes and infant growth in rural
228 Burkina Faso. Biospé study, which was nested within the MISAME-III trial, aimed to 228 Burkina Faso. Biospé study, which was nested within the MISAME-III trial, aimed to
229 evaluate the physiological effects of BEP supplementation on both pregnant and lactating 229 evaluate the physiological effects of BEP supplementation on both pregnant and lactating
230 women and their infants. women and their infants.

231 The study was implemented in six rural health center catchment areas in the district of
232 Houndé in the Hauts-Bassins region of Burkina Faso from October 2019 to December 2020. 232 Houndé in the Hauts-Bassins region of Burkina Faso from October 2019 to December 2020.
233 A total of 1.897 women aged between 15 and 40 vears with a gestational aged < 21 233 A total of 1,897 women aged between 15 and 40 years with a gestational aged < 21
234 completed weeks, and living in the study catchment villages, were enrolled in this trial. The 234 completed weeks, and living in the study catchment villages, were enrolled in this trial. The
235 habitual diet during pregnancy is nondiverse⁵¹, being predominantly based on maize with a habitual diet during pregnancy is nondiverse⁵¹, being predominantly based on maize with a supplement of leafy vegetables⁵². supplement of leafy vegetables⁵².

237 Women were randomly assigned to the prenatal intervention arms receiving either fortified
238 BEP supplements and iron-folic acid (IFA) tablets (i.e., intervention) or IFA alone (i.e., 238 BEP supplements and iron-folic acid (IFA) tablets (i.e., intervention) or IFA alone (i.e., 239 control), which is the standard of care during pregnancy in Burkina Faso. The same women 239 control), which is the standard of care during pregnancy in Burkina Faso. The same women
240 were concurrently randomized to receive either of the postnatal interventions, which 240 were concurrently randomized to receive either of the postnatal interventions, which
241 comprised fortified BEP supplementation during the first six months postpartum in 241 comprised fortified BEP supplementation during the first six months postpartum in
242 combination with IFA for the first 6 weeks (i.e. intervention) or the postpatal control which 242 combination with IFA for the first 6 weeks (i.e., intervention), or the postnatal control, which
243 comprised IFA alone for six weeks postpartum (i.e., control). Therefore, there were four study 243 comprised IFA alone for six weeks postpartum (i.e., control). Therefore, there were four study
244 orouns in MISAME-III study: (1) prenatal BEP and IFA supplementation: (2) postpatal BEP 244 groups in MISAME-III study: (1) prenatal BEP and IFA supplementation; (2) postnatal BEP
245 and IFA supplementation; (3) both pre- and postnatal BEP and IFA supplementation; or (4) 245 and IFA supplementation; (3) both pre- and postnatal BEP and IFA supplementation; or (4)
246 both pre- and postnatal IFA only supplementation. both pre- and postnatal IFA only supplementation.

²⁴⁷**Study supplements**

248 The BEP supplement is a lipid-based nutrient supplement in the form of an energy-dense
249 peanut paste fortified with multiple micronutrients. The BEP is produced by Nutriset and is 249 peanut paste fortified with multiple micronutrients. The BEP is produced by Nutriset and is
250 ready-to-consume, does not require a cold chain and is highly stable with a long shelf life. 250 ready-to-consume, does not require a cold chain and is highly stable with a long shelf life.
251 The complete nutritional composition of a daily dose of the fortified BEP is provided in S1 251 The complete nutritional composition of a daily dose of the fortified BEP is provided in S1
252 Table. On average, a daily dose of the BEP (72g) provided an energy top up of 393 kcal (36%) Table. On average, a daily dose of the BEP (72g) provided an energy top up of 393 kcal (36%

It is made available under a CC-BY 4.0 International license.

253 energy from lipids, 20% from protein, and 32% from carbohydrates) and covered at least the
254 estimated average nutritional requirements of pregnant women for 11 micronutrients, except 254 estimated average nutritional requirements of pregnant women for 11 micronutrients, except
255 calcium, phosphorous, and magnesium⁵³. A daily dose of an IFA tablets (Sidhaant Life calcium, phosphorous, and magnesium⁵³. A daily dose of an IFA tablets (Sidhaant Life
256. Science, Delhi, India) contained 65 mg of iron [form: FeH₂O₅S] and 400 µg folic acid [form: 256 Science, Delhi, India) contained 65 mg of iron [form: FeH₂O₅S] and 400 µg folic acid [form: $C_{19}H_{19}N_7O_6$]. Following Burkinabè guidelines, all enrolled women received malaria $257 \text{ }C_{19}H_{19}N_7O_6$]. Following Burkinabè guidelines, all enrolled women received malaria
258 prophylaxis (three oral doses of sulfadoxine-pyrimethamine). prophylaxis (three oral doses of sulfadoxine-pyrimethamine).

²⁵⁹**Fecal sample collection**

260 As a sub-analysis of Biospé study, fecal samples from mother-infant dyads were collected in
261 all four groups but only two groups of samples, both pre- and postnatal BEP and IFA 261 all four groups but only two groups of samples, both pre- and postnatal BEP and IFA
262 supplementation group (BEP group), and both pre- and postnatal IFA only supplementation 262 supplementation group (BEP group), and both pre- and postnatal IFA only supplementation
263 group (IFA group) have been sequenced. Maternal fecal samples (8g) were collected in a 263 group (IFA group) have been sequenced. Maternal fecal samples (8g) were collected in a
264 fecal pot and then aliquoted into sterile crvotubes (Biosigma, Cona, VE, Italy), flash-frozen 264 fecal pot and then aliquoted into sterile cryotubes (Biosigma, Cona, VE, Italy), flash-frozen
265 and transferred to a -80 °C freezer. Infant feces (8g) were collected using a 38 \times 50 cm sterile 265 and transferred to a -80 ◦C freezer. Infant feces (8g) were collected using a 38 \times 50 cm sterile
266 protection sheet (Kimberley-Clark, Irving, TX, USA) which is used like a diaper and 266 protection sheet (Kimberley-Clark, Irving, TX, USA) which is used like a diaper and 267 wrapped around the newborn, before they were transferred to a OMNIgene•GUT OM-200
268 collection kit and then sterile cryotubes for storage at -80 \circ C. The collected feces were 268 collection kit and then sterile cryotubes for storage at -80 ◦C. The collected feces were
269 assessed for consistency based on the visual Bristol scale. For liquid feces, thorough 269 assessed for consistency based on the visual Bristol scale. For liquid feces, thorough 270 homogenization was performed using a plastic spoon to mix the solid and liquid. homogenization was performed using a plastic spoon to mix the solid and liquid.

271 Fecal samples were collected from the pregnant and lactating women at inclusion into the
272 Biospé study when most of the women were in trimester 2 (19-24 weeks) and have been 272 Biospé study when most of the women were in trimester 2 (19-24 weeks) and have been
273 taken supplementation for 2-3 weeks, trimester 3 (30-34 weeks) and 1-2 (28-56 days) and 5-6 273 taken supplementation for 2-3 weeks, trimester 3 (30-34 weeks) and 1-2 (28-56 days) and 5-6
274 months (147-175 days) postpartum. Infant fecal samples were collected in 1-2 months (12-56 274 months (147-175 days) postpartum. Infant fecal samples were collected in 1-2 months (12-56 days of life) and 5-6 months (140-168 days of life) corresponding to maternal postnatal time 275 days of life) and 5-6 months (140-168 days of life) corresponding to maternal postnatal time
276 points. points.

²⁷⁷**Metagenomic library preparation and sequencing**

278 DNA extraction, library preparation, and metagenomic sequencing was performed at the UC
279 San Diego IGM Genomics Center. DNA extraction was performed using the Thermo 279 San Diego IGM Genomics Center. DNA extraction was performed using the Thermo
280 MagMAX Microbiome Ultra kit. DNA quantification was performed using picogreen dve. 280 MagMAX Microbiome Ultra kit. DNA quantification was performed using picogreen dye.
281 Roche KAPA HyperPlus and 96-UDI plates were used for library preparation. In this study. 281 Roche KAPA HyperPlus and 96-UDI plates were used for library preparation. In this study,
282 25ng of input DNA and 9 PCR cycles were used during library preparation. A shallow MiSeq 282 25ng of input DNA and 9 PCR cycles were used during library preparation. A shallow MiSeq
283 Nano sequencing run was used to normalize read sequencing depth. 2 x 150bp reads were Nano sequencing run was used to normalize read sequencing depth. 2×150 bp reads were

It is made available under a CC-BY 4.0 International license.

284 then generated on the Illumina NovaSeq 6000 at a target depth of 25 giga base-pairs per
285 sample for maternal samples and 10 giga base-pairs per sample for infant samples. sample for maternal samples and 10 giga base-pairs per sample for infant samples.

286 **Metagenomic read annotation**
287 The metagenomic sequencing re

287 The metagenomic sequencing reads were trimmed and deduplicated using FastP. All reads
288 mapping to the hg38 human genome with Bowtie2 under default settings were removed. 288 mapping to the hg38 human genome with Bowtie2 under default settings were removed.
289 Samples were profiled by mapping preprocessed reads from each sample to a previously 289 Samples were profiled by mapping preprocessed reads from each sample to a previously
290 established database of microbiome genomes (database "Deltal") using Bowtie2 with default 290 established database of microbiome genomes (database "DeltaI") using Bowtie2 with default
291 settings. The DeltaI microbial genome database was specifically created to profile non-291 settings. The DeltaI microbial genome database was specifically created to profile non-
292 industrialized infant microbiomes¹³. The resulting mapping files were analyzed using inStrain 292 industrialized infant microbiomes¹³. The resulting mapping files were analyzed using inStrain
293 orofile under default settings⁵⁴. Relative abundance of each genome was calculated using the profile under default settings⁵⁴. Relative abundance of each genome was calculated using the
294. formula: number of reads mapping to genome / number of processed reads in sample. Only 294 formula: number of reads mapping to genome / number of processed reads in sample. Only genomes with breadth > 0.5 were considered in analyses. genomes with breadth > 0.5 were considered in analyses.

296 Gene-level functional profiling was performed using the inStrain "parse_annotations" pipeline with the vertings 297 pipeline with default settings 298 (https://instrain.readthedocs.io/en/master/user_manual.html#parse-annotations). Genes were
299 called for each genome individually using Prodigal in "single" mode, and all gene files were 299 called for each genome individually using Prodigal in "single" mode, and all gene files were
300 then concatenated together. Functional annotation was performed against (1) Kvoto 300 then concatenated together. Functional annotation was performed against (1) Kyoto
301 Encyclopedia of Genes and Genomes (KEGG) Orthologies (KOs) using kofam scan (version 301 Encyclopedia of Genes and Genomes (KEGG) Orthologies (KOs) using kofam_scan (version 302 1.3): (2) carbohvdrate-active enzymes (CAZvmes) using dbCAN2 (version 11): (3) 302 1.3); (2) carbohydrate-active enzymes (CAZymes) using dbCAN2 (version 11); (3)
303 Comprehensive Antibiotic Resistance Database (CARD) Anti-Microbial Resistance (AMR) 303 Comprehensive Antibiotic Resistance Database (CARD) Anti-Microbial Resistance (AMR)
304 database version 3.2.5 using Diamond with the command "diamond blastn -f 6 -e 0.0001 -k 304 database version 3.2.5 using Diamond with the command "diamond blastp -f 6 -e 0.0001 -k
305 1"; and (4) HMO proteins using the instructions provided here: ³⁰⁵1"; and (4) HMO proteins using the instructions provided here: 306 https://instrain.readthedocs.io/en/master/user_manual.html#human-milk-oligosaccharide-
307 hmo-utilization-genes

hmo-utilization-genes.

³⁰⁸**Taxonomic data analysis**

309 Alpha-diversity metrics for Observed Species index, Simpson's Diversity index, and Shannon
310 Diversity index were calculated in R using phyloseq $v1.44.0^{55}$. The treatment effect of the Diversity index were calculated in R using phyloseq v1.44.0⁵⁵. The treatment effect of the randomized intervention was estimated by the doubly robust TMLE in R using tmle v1.5.0⁵⁶. randomized intervention was estimated by the doubly robust TMLE in R using tmle v1.5.0⁵⁶.
312 Given the likely heterogeneity of the effect between the populations, this estimation was 312 Given the likely heterogeneity of the effect between the populations, this estimation was
313 performed for maternal and infant data separately, further separated into pre- and postnatal 313 performed for maternal and infant data separately, further separated into pre- and postnatal
314 for the maternal samples. Maternal stratum data (level of education, marital status, language, 314 for the maternal samples. Maternal stratum data (level of education, marital status, language,
315 religion, ethnicity, number of iobs, socio-economic status, dietary diversity score, and health ³¹⁵religion, ethnicity, number of jobs, socio-economic status, dietary diversity score, and health

It is made available under a CC-BY 4.0 International license.

316 center), as well as anthropometric data taken at inclusion into the trial (age, height, BMI and
317 hemoglobin level) were taken as covariates for the model. Both covariate-outcome and 317 hemoglobin level) were taken as covariates for the model. Both covariate-outcome and
318 propensity score models were fitted with ensemble SuperLearner ($v2.0$ -28) models. Diversity

318 propensity score models were fitted with ensemble SuperLearner (v2.0-28) models. Diversity
319 indices were translated to effective numbers of species using the formulas posed by Jost⁵⁷.

indices were translated to effective numbers of species using the formulas posed by Jos^{57} .

320 Beta-diversity analysis was performed in R using vegan v2.6-4. Ordination was performed on
321 the weighted UniFrac distances between the log transformed strain counts, followed by 321 the weighted UniFrac distances between the log transformed strain counts, followed by
322 multivariate statistics between groups using permutational multivariate analysis of variance 322 multivariate statistics between groups using permutational multivariate analysis of variance
323 (PERMANOVA) with default parameters.

(PERMANOVA) with default parameters.

324 To address compositionality and zero-inflation issues of microbial count data, the differential
325 abundance analyses was performed by using Analysis of Compositions of Microbiomes with 325 abundance analyses was performed by using Analysis of Compositions of Microbiomes with
326 Bias Correction (ANCOM-BC) v2.2.1 at every taxonomic level separately to identify taxa 326 Bias Correction (ANCOM-BC) v2.2.1 at every taxonomic level separately to identify taxa
327 associated to the treatment intervention⁵⁸. Beniamini-Hochberg multiple testing correction associated to the treatment intervention⁵⁸. Benjamini-Hochberg multiple testing correction
328 was used, and the alpha-level was set at 0.05 . To avoid inflated false positive rate, a 328 was used, and the alpha-level was set at 0.05. To avoid inflated false positive rate, a
329 sensitivity analysis was conducted against the addition of pseudo-counts. Only robustly 329 sensitivity analysis was conducted against the addition of pseudo-counts. Only robustly significant taxa were reported. significant taxa were reported.

³³¹**Functional data analysis**

332 A hierarchical differential abundance analyses was conducted on the Trimmed Mean of M-
333 values (TMM) library sizes for the gene counts using treeclimbR v0.1.5 and edgeR in R^{59} . values (TMM) library sizes for the gene counts using treeclimbR v0.1.5 and edgeR in R^{59} .
334. Genes from KEGG, HMO, CAZyme and CARD were categorized into a hierarchical 334 Genes from KEGG, HMO, CAZyme and CARD were categorized into a hierarchical
335 structure based on their respective Enzymatic Class (EC) number, functional group, HMO 335 structure based on their respective Enzymatic Class (EC) number, functional group, HMO
336 cluster or antibiotic resistance mechanism Benjamini-Hochberg multiple testing correction 336 cluster or antibiotic resistance mechanism. Benjamini-Hochberg multiple testing correction
337 was used, and the alpha-level was set at 0.05 . was used, and the alpha-level was set at 0.05.

338 Using the KEGG pathway mappings, we performed a Gene Set Enrichment Analysis to
339 identify pathways that were differentially abundant in a coordinated direction⁶⁰. A identify pathways that were differentially abundant in a coordinated direction⁶⁰. A 340 *Bifidobacterium longum* NagR regulon gene set was also added for the HMO utilization 340 *Bifidobacterium longum* NagR regulon gene set was also added for the HMO utilization
341 genes found in Table 1 of Arzamasov et. al $(2022)^{61}$. For each set, an enrichment score with a genes found in Table 1 of Arzamasov et. al $(2022)^{61}$. For each set, an enrichment score with a
342. corresponding adjusted p-value was calculated in R using clusterProfiler v4.2.2⁶². The alphacorresponding adjusted p-value was calculated in R using clusterProfiler v4.2.2⁶². The alpha-
143 level was set at 0.05 and the minimum gene set size to 1. level was set at 0.05 and the minimum gene set size to 1.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

³⁴⁴**Ethics**

345 The study was approved by the Commissie voor Medische Ethiek (CME) of Ghent
346 Iniversity Hospital (protocol code: B670201734334 and date of 10/08/2020) and the Comité 346 University Hospital (protocol code: B670201734334 and date of 10/08/2020) and the Comité
347 d'Éthique Institutionnel de la Recherche En Sciences de la Santé (CEIRES) of the Institut de 347 d'Éthique Institutionnel de la Recherche En Sciences de la Santé (CEIRES) of the Institut de
348 Recherche en Sciences de la Santé (IRSS) (protocol code 50-2020/CEIRES and date of 348 Recherche en Sciences de la Santé (IRSS) (protocol code 50-2020/CEIRES and date of 349 22/10/2020). An independent Data and Safety Monitoring Board (DSMB), comprising an 349 22/10/2020). An independent Data and Safety Monitoring Board (DSMB), comprising an
350 endocrinologist, two pediatricians, a gynecologist, and an ethicist of both Belgian and 350 endocrinologist, two pediatricians, a gynecologist, and an ethicist of both Belgian and
351 Burkinabe nationalities, was established prior to the start of the efficacy trial. The DSMB 351 Burkinabe nationalities, was established prior to the start of the efficacy trial. The DSMB
352 managed remote safety reviews for adverse and serious events at nine and 20 months after the 352 managed remote safety reviews for adverse and serious events at nine and 20 months after the
353 start of enrolment. The MISAME-III trial was registered on *ClinicalTrials gov* (identifier: 353 start of enrolment. The MISAME-III trial was registered on *ClinicalTrials.gov* (identifier:
354 NCT03533712). NCT03533712).

³⁵⁵**Author Contributions**

356 LD and ST performed the statistical analyses, visualized data, interpreted data, and prepared
357 the manuscript with contributions from all authors. MRO, EDS, and JLS were responsible for

357 the manuscript with contributions from all authors. MRO, EDS, and JLS were responsible for
358 the sample analysis, interpreted preliminary data and critically reviewed the manuscript.

358 the sample analysis, interpreted preliminary data and critically reviewed the manuscript.
359 TDC, LCT, CL and PK conceived of the study, acquired funding, and critically reviewed

359 TDC, LCT, CL and PK conceived of the study, acquired funding, and critically reviewed the
360 manuscript. TDC, LCT, LO, YBM, MO, RG, CL, and PK set up the study and supervised the

360 manuscript. TDC, LCT, LO, YBM, MO, RG, CL, and PK set up the study and supervised the
361 project. TDC, LO, YBM, MO and RG collected samples. TDC, EB, AA, KT, WVC, and MS

361 project. TDC, LO, YBM, MO and RG collected samples. TDC, EB, AA, KT, WVC, and MS
362 supervised the data curation and contributed to data interpretation.

362 supervised the data curation and contributed to data interpretation.
363 All authors have read and agreed to the published version of the ma

All authors have read and agreed to the published version of the manuscript.

³⁶⁴**Acknowledgements**

- 365 The work is supported by the Bill & Melinda Gates Foundation (OPP1175213). Lishi Deng is
366 supported by the China Scholarship Council (Grant No. 202207650056). Steff Taelman is
- 366 supported by the China Scholarship Council (Grant No. 202207650056). Steff Taelman is
367 supported by the Flemish Agency for Innovation and Entrepreneurship (VLAIO
- 367 supported by the Flemish Agency for Innovation and Entrepreneurship (VLAIO
368 HBC.2020.2292). This publication includes data generated at the UC San Diego
- 368 HBC.2020.2292). This publication includes data generated at the UC San Diego IGM
369 Genomics Center utilizing an Illumina NovaSeq 6000 that was purchased with funding
- 369 Genomics Center utilizing an Illumina NovaSeq 6000 that was purchased with funding from
370 a National Institutes of Health SIG grant (#S10 OD026929). The funders had no role in the
- 370 a National Institutes of Health SIG grant (#S10 OD026929). The funders had no role in the
371 design and conduct of the study: in the collection, management, analysis, and interpretation
- 371 design and conduct of the study; in the collection, management, analysis, and interpretation
372 of the data: or in the preparation, review, or approval of the manuscript.
- 372 of the data; or in the preparation, review, or approval of the manuscript.
373 The authors thank all participants from Burkina Faso and the data collection-
- 373 The authors thank all participants from Burkina Faso and the data collection team. We thank
374 Nutriset (France) for donating the BEP supplements.
- Nutriset (France) for donating the BEP supplements.

It is made available under a CC-BY 4.0 International license.

³⁷⁵**Data Availability Statement**

- 376 The informed consent form does not allow sharing of personal data outside the research team.
377 Data will be made available through a data-sharing agreement. Please contact
- 377 Data will be made available through a data-sharing agreement. Please contact
378 carl.lachat@ugent.be for any queries. Supporting study documents, including t
- 378 carl.lachat@ugent.be for any queries. Supporting study documents, including the study
379 protocol and questionnaires, are publicly available on the study's website:
- 379 protocol and questionnaires, are publicly available on the study's website:
380 https://misame3.ugent.be (accessed on 23 November 2023).
- https://misame3.ugent.be (accessed on 23 November 2023).

³⁸¹**Informed Consent Statement**

Informed consent was obtained from all subjects involved in the study.

³⁸³**Competing Interests**

The authors have declared no competing interests.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Tables and figures

Values are percentages or means ± SDs.
*Assessed using FANTA/USAID's Household Food Insecurity Access Scale.

EBF, exclusive breastfeeding; BMI, body mass index; Hb, hemoglobin; SD, standard deviation.

It is made available under a CC-BY 4.0 International license.

Figure 1: Flow diagram of recruitment, enrollment, and stool sample collection from women and their infants. BEP, balanced energy-protein; IFA, iron-folic acid.

It is made available under a CC-BY 4.0 International license.

Figure 2: **(A)** Taxonomic compositions of the top-15 most abundant genera (on average across all samples) aggregated on the treatment- and time groups. The lesser abundant genera are grouped into the "Other" category. **(B)** A PCoA ordination plot of the infant samples. Samples are colored based on the treatment group. **(C)** A PCoA ordination plot of the maternal samples, colored on treatment group. **(D)** The taxonomic tree of the strains identified across all samples, colored on phylum. **(E)** Combined box- and jitter plots of the Shannon diversity indices of the samples, grouped on pre- and postnatal, and on whether the sample was isolated from the infant or the mother, colored on treatment group. Abbreviation: pn12, postnatal 1-2 months; pn56, postnatal 5-6 months; incl., inclusion; tri3, trimester 3.

Figure 3: Volcano plots showing differential taxa between two treatment groups at different time points, by ANCOM-BC2. Each point represents an individual taxon, and the position along the x-axis represents logFC in its abundance. The dashed line and labels show the thresholds of statistical and biological significance (Benjamini-Hochberg adjusted *p*-values < 0.05 and |logFC| > 1). The colored dots represent significantly enriched (blue) and depleted (red) taxa that have successfully passed the sensitivity analysis for pseudo-counts. A full table of outputs from ANCOM-BC2 at each time point can be found in Table S2.

. [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) It is made available under a

It is made available under a CC-BY 4.0 International license

Figure 4: Significantly enriched or depleted KEGG pathways associated to BEP supplementation for each time point. Abbreviation: pn12, postnatal 1-2 months; pn56, postnatal 5-6 months; incl., inclusion; tri3, trimester 3. Points are colored according to adjusted p-value lue and point size corresponds to gene set size.

. [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) It is made available under a

It is made available under a CC-BY 4.0 International license

It is made available under a CC-BY 4.0 International license.

logFC 0.10

 $+$ O Lipid X

.
Lipid IIs

O Deac vi-linid IV B

D-glyce ro.
9-D-manaio
Herdose-7P

D-glycero-
B-D-manno
Herdose-7P

LpmB

 δ Lipid A disaccha

 $.9t$

GIONAGE1 WabE GloNa1- G IcA β 1 -.
Galer

akit
WaaX

Weel1

Waak

out

Glor WaaD
WaaH

Waat $0.95 -$

um) GloNAca1

WaaK

O PS WaaL

WaaL

.
ca su Ari wnae IIIa)

GIONACO

WaaR

WaaY

Mature LPS

 \rightarrow 0 231251

 0.00

 -0.10

 -0.20

 -0.30

D-Ribulose-5F

WabA EptB

Gala1PEtN

Pentose phosphat

edoheptulose-7F

UDP-3-O-(3-hyd

KDO-
lipid IV A

UDP-N-acetyl
D-glucosamine

KDO2-lipid IV ${\bf A}$

 $1 - 1$

ACP O-

4-Phospho-
KDO-Epid IVA O + 271166

 $[23120]$

UDP-3-0-(3-hy

Lipid IV A

2.42.43

Strangy
PKDO2-lipid IV A $\frac{23128}{2}$ \bullet O -242.43 Lauroyl-
KDO2-lipid IV 231251 Lipid IVB
PagL Palmitoleovi
KDO2-lipid IV A Palmitoleoyi-n
KDO2-lipid A Myristoyl-ACP O L_{F} M $\boxed{231248}$ $LpxJ$ ACPO⁴ KDO2-lipid A $-0 - 231251$ 231251 > C Palmitoylated Pagl. $KDO2-IpidA$ 04 LpxO Dearyl-lipid IVA $\frac{1.048 \times 10^{-10}}{2.7738} = 0 = \frac{1.048 \times 10^{-10}}{3.13.45} = 0 = \frac{1.048 \times 10^{-10}}{2.51.55} = 0 = \frac{5.3113}{5} = 0 = -1.048$ $LpcE$ $\begin{array}{r} \text{L-AraAN-} \\ \text{KDO2-irid A} \\ \hline 2.42.43 \end{array}$ 3'-O-Deacylated O<- LpxR 3-Deoxy-
D-manno CMP-3-deoxy-D 3-Deoxy-
D-manzo-1-Dephosphorylated
KDO2-lipid A EptA^T KDO2-lipid A 04 27.429 $-0 - 27771$ $-0 - 31383$ \circ S-layer
glycopa GDP-D-glyce to-1. PE01. D-glycero-
%D-manao
Hermon, 19 D-glyce ro-
0-D-manno-
Heptose-1,7P2 $\frac{EptB}{2.7.8.42}$ \rightarrow O $\frac{PEM.KDOB}{hpidA}$ KdoH 321144 KDO2-lipid A
1-(2-aminoethyl
dinhosnhate) KDO O⁴ KDO2-lipid #
1.4'-bin-(2-an .
brdtas 1-PEN-
KDO-lipid A ∾ ⊶ ≘⊶ ADP-L-glycero-ADP-D-glycero-
β-D-manno-heptose β-D-manno-heptose D-glycero-
β-D-manno-
Heptose-1,7P2 LpxF iarino
se 1P

Outer core OS

 $O-PS$

4'-Dephosphorylated
1-PEtN-KDO-hpid A

(E. cošR3) GloNAca1

GleNe11

 G IcA β 1 \neg

(E. cokK-12, R2,

Inner Core oligosaccharide (OS)

 $(E \cosh R1)$

LpgR KDO-lipid A $\sum_{(be\,\text{brac}\,\text{v}\text{d}\text{u}\text{d}\text{u})}$

PEtN

LRhau1
(EcošK-12)

WabA EptB

(E. coll R2) Galat PEth

 \mathcal{Z} and

LIPOPOLYSACCHARIDE BIOSYNTHESIS

(*H. pylon*)
KDO2-lipid IV A

Stearovi-ACP

ACP O

Amino sugar and
nucleotide sugar metabolism

Lauroyd-ACP O

Figure 5: The lipopolysaccharide biosynthesis KEGG pathway (map00540⁶³) in maternal samples during the third trimester of pregnancy. Genes colored in yellow, green, and blue are incrementally less abundantly observed in the BEP-supplemented group. Genes colored in red are more abundantly observed in the BEP-supplemented group.

 $(E.\text{col }R1)$

 $(E.\cosh R4)$

 $(E.\coth K-12)$

 $(E.\cosh R2)$

 $(E.\cosh R3)$

(S. enterica su typhimuri

It is made available under a CC-BY 4.0 International license.

Table S1: Nutritional values of the ready-to-use supplementary food for pregnant and lactating women.

Table S2: Results of the differential abundance analyses between intervention groups.

Table S3: Results of the gene set enrichment analyses between intervention groups.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Figure S1: The number of samples versus the number of bases sequenced per sample for various gut metagenomic datasets and this study (adapted from (Carter et al., $2023)^{64}$).

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

Figure S2: The phosphotransferase system KEGG pathway (map 02060^{63}) in maternal samples during the third trimester of pregnancy. Genes colored in red, yellow, green, and blue are incrementally less abundantly observed in the BEP-supplemented group.

It is made available under a CC-BY 4.0 International license.

the third trimester of pregnancy. Genes colored in yellow, green, and blue are incrementally less abundantly observed in the BEP-supplemented group. Genes colored in red are more abundantly observed in the BEP-supplemented group.

It is made available under a CC-BY 4.0 International license.

Figure S4: The flagellar assembly KEGG pathway (map 02040^{63}) in maternal samples during the third trimester of pregnancy. Genes colored in red, yellow, green, and blue are incrementally less abundantly observed in the BEP-supplemented group.

It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

References

- 1. Levels and trends in child malnutrition: UNICEF/WHO/World Bank Group joint child malnutrition estimates: key findings of the 2023 edition. https://www.who.int/publications-detail-redirect/9789240073791 (2023).
- 2. Black, R. E. et al. Maternal and child undernutrition and overweight in low-income and middle-income countries. The Lancet **382**, 427–451 (2013).
- 3. Martorell, R., Khan, K. & Schroeder, D. G. Reversibility of stunting \Box : epidemiological findings in children from developing countries. Reversibility Stunting Epidemiol. Find. Child. Dev. Ctries. **48**, S45–S57 (1994).
- 4. Victora, C. G., de Onis, M., Hallal, P. C., Blössner, M. & Shrimpton, R. Worldwide Timing of Growth Faltering: Revisiting Implications for Interventions. Pediatrics **125**, e473–e480 (2010).
- 5. Victora, C. G. et al. Revisiting maternal and child undernutrition in low-income and middle-income countries: variable progress towards an unfinished agenda. The Lancet **397**, 1388–1399 (2021).
- 6. Adu-Afarwuah, S. et al. Small-quantity, lipid-based nutrient supplements provided to women during pregnancy and 6 mo postpartum and to their infants from 6 mo of age increase the mean attained length of 18-mo-old children in semi-urban Ghana: a randomized controlled trial12. Am. J. Clin. Nutr. **104**, 797–808 (2016).
- 7. Argaw, A. et al. Fortified balanced energy–protein supplementation during pregnancy and lactation and infant growth in rural Burkina Faso: A 2 \times 2 factorial individually randomized controlled trial. PLOS Med. **20**, e1004186 (2023).
- 8. Dewey, K. G. et al. Lipid-based nutrient supplementation in the first 1000 d improves child growth in Bangladesh: a cluster-randomized effectiveness trial1, 2, 3. Am. J. Clin. Nutr. **105**, 944–957 (2017).

It is made available under a CC-BY 4.0 International license. medRxiv preprint doi: [https://doi.org/10.1101/2023.11.24.23298964;](https://doi.org/10.1101/2023.11.24.23298964) this version posted November 27, 2023. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has grante

- 9. Galasso, E., Weber, A. M., Stewart, C. P., Ratsifandrihamanana, L. & Fernald, L. C. H. Effects of nutritional supplementation and home visiting on growth and development in young children in Madagascar: a cluster-randomised controlled trial. Lancet Glob. Health **7**, e1257–e1268 (2019).
- 10. Krebs, N. F. et al. Growth from Birth Through Six Months for Infants of Mothers in the "Women First" Preconception Maternal Nutrition Trial. J. Pediatr. **229**, 199-206.e4 (2021).
- 11. De Filippo, C. et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl. Acad. Sci. **107**, 14691–14696 (2010).
- 12. Grzeskowiak, L. et al. Distinct Gut Microbiota in Southeastern African and Northern European Infants. J. Pediatr. Gastroenterol. Nutr. **54**, 812 (2012).
- 13. Olm, M. R. et al. Robust variation in infant gut microbiome assembly across a spectrum of lifestyles. Science **376**, 1220–1223 (2022).
- 14. Bezirtzoglou, E., Tsiotsias, A. & Welling, G. W. Microbiota profile in feces of breast- and formula-fed newborns by using fluorescence in situ hybridization (FISH). Anaerobe **17**, 478–482 (2011).
- 15. Stewart, C. J. et al. Temporal development of the gut microbiome in early childhood from the TEDDY study. Nature **562**, 583–588 (2018).
- 16. Ottman, N., Smidt, H., de Vos, W. & Belzer, C. The function of our microbiota: who is out there and what do they do? Front. Cell. Infect. Microbiol. **2**, (2012).
- 17. Yatsunenko, T. et al. Human gut microbiome viewed across age and geography. Nature **486**, 222–227 (2012).
- 18. Alderete, T. L. et al. Early life gut microbiota is associated with rapid infant growth in Hispanics from Southern California. Gut Microbes **13**, 1961203 (2021).
- 19. Iddrisu, I. et al. Malnutrition and Gut Microbiota in Children. Nutrients **13**, 2727 (2021).
- 20. Subramanian, S. et al. Persistent gut microbiota immaturity in malnourished Bangladeshi children. Nature **510**, 417–421 (2014).
- 21. Arox W, K. et al. Provision of Lipid-Based Nutrient Supplements to Mothers During Pregnancy and 6 Months Postpartum and to Their Infants from 6 to 18 Months Promotes Infant Gut Microbiota Diversity at 18 Months of Age but Not Microbiota Maturation in a Rural Malawian Setting: Secondary Outcomes of a Randomized Trial. J. Nutr. **150**, 918– 928 (2020).
- 22. Kortekangas, E. et al. A Prospective Study on Child Morbidity and Gut Microbiota in Rural Malawi. J. Pediatr. Gastroenterol. Nutr. **69**, 431 (2019).
- 23. de Kok, B. et al. Fortified Balanced Energy-Protein Supplements Increase Nutrient Adequacy without Displacing Food Intake in Pregnant Women in Rural Burkina Faso. J. Nutr. **151**, 3831–3840 (2021).
- 24. De Kok, B. et al. Prenatal fortified balanced energy-protein supplementation and birth outcomes in rural Burkina Faso: A randomized controlled efficacy trial. PLOS Med. **19**, e1004002 (2022).
- 25. Abdill, R. J., Adamowicz, E. M. & Blekhman, R. Public human microbiome data are dominated by highly developed countries. PLOS Biol. **20**, e3001536 (2022).
- 26. Kotrba, P., Inui, M. & Yukawa, H. Bacterial phosphotransferase system (PTS) in carbohydrate uptake and control of carbon metabolism. J. Biosci. Bioeng. **92**, 502–517 (2001).
- 27. Matsuki, T. et al. A key genetic factor for fucosyllactose utilization affects infant gut microbiota development. Nat. Commun. **7**, 11939 (2016).
- 28. Scheppach, W. Effects of short chain fatty acids on gut morphology and function. Gut **35**, S35–S38 (1994).
- 29. De Goffau, M. C. et al. Gut microbiomes from Gambian infants reveal the development of a non-industrialized Prevotella-based trophic network. Nat. Microbiol. **7**, 132–144 (2021).
- 30. Pickard, J. M., Zeng, M. Y., Caruso, R. & Núñez, G. Gut microbiota: Role in pathogen colonization, immune responses, and inflammatory disease. Immunol. Rev. **279**, 70–89 (2017).
- 31. Gulhane, M. et al. High Fat Diets Induce Colonic Epithelial Cell Stress and Inflammation that is Reversed by IL-22. Sci. Rep. **6**, 28990 (2016).
- 32. Di Gesù, C. M., Matz, L. M. & Buffington, S. A. Diet-induced dysbiosis of the maternal gut microbiome in early life programming of neurodevelopmental disorders. Neurosci. Res. **168**, 3–19 (2021).
- 33. Chakaroun, R. M., Massier, L. & Kovacs, P. Gut Microbiome, Intestinal Permeability, and Tissue Bacteria in Metabolic Disease: Perpetrators or Bystanders? Nutrients **12**, 1082 (2020).
- 34. Bradley, P. H. & Pollard, K. S. Proteobacteria explain significant functional variability in the human gut microbiome. Microbiome **5**, 36 (2017).
- 35. Coats, S. R. et al. The Lipid A Phosphate Position Determines Differential Host Toll-Like Receptor 4 Responses to Phylogenetically Related Symbiotic and Pathogenic Bacteria. Infect. Immun. **79**, 203–210 (2011).
- 36. Schromm, A. B. et al. Biological activities of lipopolysaccharides are determined by the shape of their lipid A portion: Bioactivity of LPS determined by lipid A shape. Eur. J. Biochem. **267**, 2008–2013 (2000).
- 37. Ravi, A. et al. Linking carbohydrate structure with function in the human gut microbiome using hybrid metagenome assemblies. 2021.05.11.441322 Preprint at https://doi.org/10.1101/2021.05.11.441322 (2021).
- 38. Deutscher, J., Francke, C. & Postma, P. W. How Phosphotransferase System-Related Protein Phosphorylation Regulates Carbohydrate Metabolism in Bacteria. Microbiol. Mol. Biol. Rev. **70**, 939–1031 (2006).
- 39. Schneider, E. ABC transporters catalyzing carbohydrate uptake. Res. Microbiol. **152**, 303–310 (2001).
- 40. Patrick, S. A tale of two habitats: Bacteroides fragilis, a lethal pathogen and resident in the human gastrointestinal microbiome. Microbiology **168**, 001156 (2022).
- 41. Briliūtė, J. et al. Complex N-glycan breakdown by gut Bacteroides involves an extensive enzymatic apparatus encoded by multiple co-regulated genetic loci. Nat. Microbiol. **4**, 1571–1581 (2019).
- 42. Liu, J. et al. Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study. The Lancet **388**, 1291–1301 (2016).
- 43. Schnee, A. E. & Petri, W. A. Campylobacter jejuni and associated immune mechanisms: short-term effects and long-term implications for infants in low-income countries. Curr. Opin. Infect. Dis. **30**, 322–328 (2017).
- 44. Bian, X. et al. Campylobacter Abundance in Breastfed Infants and Identification of a New Species in the Global Enterics Multicenter Study. mSphere **5**,

10.1128/msphere.00735-19 (2020).

- 45. Xi, M. et al. Functional proteins in breast milk and their correlation with the development of the infant gut microbiota: a study of mother-infant pairs. Front. Microbiol. **14**, 1239501 (2023).
- 46. Laxminarayan, R. & Bhutta, Z. A. Antimicrobial resistance—a threat to neonate survival. Lancet Glob. Health **4**, e676–e677 (2016).
- 47. Rodrigues, C. et al. Description of Klebsiella africanensis sp. nov., Klebsiella variicola subsp. tropicalensis subsp. nov. and Klebsiella variicola subsp. variicola subsp. nov. Res. Microbiol. **170**, 165–170 (2019).
- 48. Ouyang, R. et al. Crosstalk between Breast Milk N-Acetylneuraminic Acid and Infant Growth in a Gut Microbiota-Dependent Manner. Metabolites **13**, 846 (2023).
- 49. Vanslambrouck, K. et al. Effect of balanced energy-protein supplementation during pregnancy and lactation on birth outcomes and infant growth in rural Burkina Faso: study protocol for a randomised controlled trial. BMJ Open **11**, e038393 (2021).
- 50. Bastos-Moreira, Y. et al. A Multi-Omics and Human Biomonitoring Approach to Assessing the Effectiveness of Fortified Balanced Energy–Protein Supplementation on Maternal and Newborn Health in Burkina Faso: A Study Protocol. Nutrients **15**, 4056 (2023).
- 51. Hanley-Cook, G. T. et al. Seasonality and Day-to-Day Variability of Dietary Diversity: Longitudinal Study of Pregnant Women Enrolled in a Randomized Controlled Efficacy Trial in Rural Burkina Faso. J. Nutr. **152**, 2145–2154 (2022).
- 52. Huybregts, L. F., Roberfroid, D. A., Kolsteren, P. W. & Van Camp, J. H. Dietary behaviour, food and nutrient intake of pregnant women in a rural community in Burkina Faso. Matern. Child. Nutr. **5**, 211–222 (2009).
- 53. Food and Nutrition Board, Institute of Medicine & National Academies. Dietary Reference Intakes (DRIs): Recommended Dietary Allowances and Adequate Intakes, Vitamins. https://www.ncbi.nlm.nih.gov/books/NBK56068/table/summarytables.t2/ (2011).
- 54. Olm, M. R. et al. inStrain profiles population microdiversity from metagenomic data and sensitively detects shared microbial strains. Nat. Biotechnol. **39**, 727–736 (2021).
- 55. McMurdie, P. J. & Holmes, S. phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data. PLoS ONE **8**, e61217 (2013).
- 56. Gruber, S. & Laan, M. J. V. D. tmle: Package for Targeted Maximum Likelihood Estimation. J. Stat. Softw. **51**, (2012).
- 57. Jost, L. Entropy and diversity. Oikos **113**, 363–375 (2006).
- 58. Lin, H. & Peddada, S. D. Analysis of compositions of microbiomes with bias correction. Nat. Commun. **11**, 3514 (2020).
- 59. Huang, R. et al. treeclimbR pinpoints the data-dependent resolution of hierarchical hypotheses. Genome Biol. **22**, 157 (2021).
- 60. Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. **102**, 15545–15550 (2005).
- 61. Arzamasov, A. A. et al. Human Milk Oligosaccharide Utilization in Intestinal Bifidobacteria Is Governed by Global Transcriptional Regulator NagR. mSystems **7**, e00343-22 (2022).
- 62. Wu, T. et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. The Innovation **2**, 100141 (2021).
- 63. Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. (2000).
- 64. Carter, M. M. et al. Ultra-deep sequencing of Hadza hunter-gatherers recovers vanishing gut microbes. Cell **186**, 3111-3124.e13 (2023).

CONSORT 2010 checklist of information to include when reporting a randomised trial*

Citation: Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Medicine. 2010;8:18. © 2010 Schulz et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up-to-date references relevant to this checklist, see www.consort-statement.org.

. [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) It is made available under a